Welcome to GenPrice! Check out our latest updates.

Shopping Cart (0)

Your cart is empty

Add some products to get started!

Purmorphamine

Purmorphamine is a smoothened/Smo receptor agonist with an EC50 of 1 μM.

Product Specifications

CAS Number

483367-10-8

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Autophagy; Organoid; Smo

Type

Reference compound

Related Pathways

Autophagy; Stem Cell/Wnt

Applications

Cancer-Kinase/protease

Field of Research

Neurological Disease; Cancer

Assay Protocol

https://www.medchemexpress.com/Purmorphamine.html

Purity

99.9

Solubility

DMSO : 33.33 mg/mL (ultrasonic)

Smiles

N1(C2=CC=C(NC3=NC(OC4=CC=CC5=C4C=CC=C5)=NC6=C3N=CN6C7CCCCC7)C=C2)CCOCC1

Molecular Formula

C31H32N6O2

Molecular Weight

520.62

Precautions

H302, H315, H319, H335

References & Citations

[1]Beloti MM, et al. Purmorphamine enhances osteogenic activity of human osteoblasts derived from bone marrow mesenchymal cells. Cell Biol Int. 2005 Jul;29 (7) :537-41.. . . .|[2]Gu D, et al. A role for transcription factor STAT3 signaling in oncogene smoothened-driven carcinogenesis. J Biol Chem. 2012 Nov 2;287 (45) :38356-66.|[3]Beloti MM, et al. Purmorphamine enhances osteogenic activity of human osteoblasts derived from bone marrow mesenchymal cells. Cell Biol Int. 2005 Jul;29 (7) :537-41.

Shipping Conditions

Room Temperature

Storage Conditions

-20°C, 3 years; 4°C, 2 years (Powder)

Scientific Category

Reference compound1

Clinical Information

No Development Reported

Citation 01

Adv Sci (Weinh) . 2025 May;12 (17) :e2411235.|Am J Physiol Cell Physiol. 2025 Oct 8.|Arthritis Res Ther. 2024 Jan 25;26 (1) :36.|Biochem Biophys Res Commun. 2021 Oct 15:574:1-7.|Burns Trauma. 2019 Sep 23;7:29.|Cancer Med. 2018 Nov;7 (11) :5704-5715.|Cell. 2025 Jun 26;188 (13) :3441-3458.e25.|Int J Mol Sci. 2024 Apr 9, 25 (8), 4138.|J Exp Clin Cancer Res. 2018 Nov 27;37 (1) :287. |J Hazard Mater. 2025 Oct 17:499:140149.|Med Oncol. 2021 Mar 17;38 (4) :41.|Mil Med Res. 2020 Nov 1;7 (1) :52.|Mil Med Res. 2020 Sep 6;7 (1) :42.|Mol Cell Toxicol. 2025 Oct 23.|Oncol Lett. 2019 Sep;18 (3) :3081-3091.|Patent. US20180263995A1.|Pharmacol Res. 2021 Mar:165:105460.|Res Sq. 2025 Apr 24.|Transl Neurodegener. 2024 Oct 29;13 (1) :53.|Life Sci. 2023 Sep 15:329:121990.

Available Sizes

Frequently Asked Questions

More Discoveries

Explore Other Products

Browse additional items from our catalog

FGFR4-IN-5
orb1692896-01 25 mg

FGFR4-IN-5

Sign In for Pricing
View Details
FGFR4-IN-5
orb1692896-02 50 mg

FGFR4-IN-5

Sign In for Pricing
View Details
FGFR4-IN-5
orb1692896-03 100 mg

FGFR4-IN-5

Sign In for Pricing
View Details
LOC100504608 3'UTR Luciferase Stable Cell Line
TU112111 1.0 mL

LOC100504608 3'UTR Luciferase Stable Cell Line

Sign In for Pricing
View Details
T7 High Yield RNA Synthesis Kit
K777627-50 50 Reactions

T7 High Yield RNA Synthesis Kit

Sign In for Pricing
View Details
Human Claudin 1 (CLDN1) ELISA kit
CK-bio-10882-01 48 Tests

Human Claudin 1 (CLDN1) ELISA kit

Sign In for Pricing
View Details